A Study Assessing Treatment Uptake And Real World Effectiveness Of Sofosbuvir/Ledipasvir (SOF/LDV) And Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD)Among HCV-Infected Patients With Chronic Kidney Disease (CKD)
Latest Information Update: 25 May 2017
Price :
$35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017.